Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Asian Pacific Journal of Tropical Medicine ; 15(9):400-409, 2022.
Article in English | EMBASE | ID: covidwho-2080621


Objective: To evaluate long-term effects of COVID-19, and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society (TTS)-TURCOVID multicenter registry. Method(s): Thirteen centers participated with 831 patients;504 patients were enrolled after exclusions. The study was designed in three-steps: (1) Phone questionnaire;(2) retrospective evaluation of the medical records;(3) face-to-face visit. Result(s): In the first step, 93.5% of the patients were hospitalized;61.7% had a history of pneumonia at the time of diagnosis. A total of 27.1% reported clinical symptoms at the end of the first year. Dyspnea (17.00%), fatigue (6.30%), and weakness (5.00%) were the most prevalent long-term symptoms. The incidence of long-term symptoms was increased by 2.91 fold (95% CI 1.04-8.13, P=0.041) in the presence of chronic obstructive pulmonary disease and by 1.84 fold (95% CI 1.10-3.10, P=0.021) in the presence of pneumonia at initial diagnosis, 3.92 fold (95% Cl 2.29-6.72, P=0.001) of dyspnea and 1.69 fold (95% Cl 1.02-2.80, P=0.040) fatigue persists in the early-post-treatment period and 2.88 fold (95% Cl 1.52-5.46, P=0.001) in the presence of emergency service admission in the post COVID period. In step 2, retrospective analysis of 231 patients revealed that 1.4% of the chest X-rays had not significantly improved at the end of the first year, while computed tomography (CT) scan detected fibrosis in 3.4%. In step 3, 138 (27.4%) patients admitted to face-to-face visit at the end of first year;at least one symptom persisted in 49.27% patients. The most common symptoms were dyspnea (27.60%), psychiatric symptoms (18.10%), and fatigue (17.40%). Thorax CT revealed fibrosis in 2.4% patients. Conclusion(s): COVID-19 symptoms can last for extended lengths of time, and severity of the disease as well as the presence of comorbidities might contribute to increased risk. Long-term clinical issues should be regularly evaluated after COVID-19. Copyright © 2022 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer Medknow.

Flora Infeksiyon Hastaliklari Ve Klinik Mikrobiyoloji Dergisi ; 26(2):267-276, 2021.
Article in Turkish | Web of Science | ID: covidwho-1524410


Introduction: The management of the patients with COVID-19 is depend on the clinical presentation. We aimed to evaluate the hospitalization rates due to the progression of the illness in the fist month, the mortality and reinfection rates of the patients with mild COVID-19 during the six months follow-up. Materials and Methods: The study with retrospective design included all SARS CoV-2 PCR positive patients presenting with mild disease to our hospital and who were recommended at-home follow-up during the first month of the COVID-19 pandemic. Demographic characteristics, baseline symptoms, laboratory results and the treatments administered were recorded. The patients were called by phone at six months after the diagnosis. Patients were asked to report hospitalisation at first month, hospitalisation due to any reason and possi- ble reinfections and current symptoms at six month. We noted the mortality rates at first month and at six months from hospital records. Results: The study included 210 patients;130 patients were male. The mean age was 42.3 +/- 15.7 (16-96) years. At baseline, 168 patients (80%) were symptomatic. Fifty-two patients (75.2%) had comorbidities. Thorax computed tomography (CT) was congruent with COVID-19 infection in 46 patients (26%). Twenty-seven patients (16.5%) were hospitalised due to the progression of clinical condition and four (2.4%) needed intensive care transmission. In multivariate analysis, those with comorbidity had having 8.2 fold (95%CI 2.2933.12) D-dimer >= 1 ug/mL had 17.8 fold (OR: 17.8, %95 GA: 3.42-113.3), and diffuse infiltrations in thorax CT scan had 5.36-fold (95% CI 1.46-21.76) higher relative risk for post-COVID hospitalisation. Two (4.1%) out of 48 patients younger than 50 years old and with no risk factors and a normal thorax CT needed hospitalisation. There was no mortality at first month. Four patients (1.9%) died due to deterioration of underlying condition during the six-month follow up. Six patients (3.6%) were considered to be reinfected six months after the first episode. Twenty-six patients (15.6%) had current symptoms which they belived had occured after COVID-19 infection. Conclusion: In the case of the presence of comorbidities, high D-dimer value and diffuse infiltration in thorax CT scan in mild COVID-19 patients, hospitalisation may be the optimal approach.